ArticleBiochemistry2026
Improved Stability and Brightness Following Iterative Redesign of a De Novo Biliprotein.
Article in Biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bilins, linear tetrapyrroles derived from heme catabolism, are ubiquitous across biological systems. The constraints imposed by binding to a protein confer valuable optical properties on bilins, which are used for sensing and harvesting light, and offer potential for fluorescence imaging, optogenetics, and biosensing. Recently, bilins have been used to evaluate methods for designing ligand binding sites, and novel biliproteins (BPs) that bind phycoerythrobilin (PEB) emerged from computational design using RoseTTAFold Diffusion All-Atom (RFDiffusionAA) and LigandMPNN. Here, we find much lower stability, extinction coefficients and fluorescence quantum yields for de novo designs compared to the native CpcA-PEB biliprotein, so we used a LigandMPNN-AlphaFold 3 (AF3)-Rosetta Relax pipeline to redesign one BP, C11, which can be implemented quickly and without in-house GPUs. The top three ligand confidence scores emerging from this procedure yielded C11-578, C11-620, and C11-756 redesigns that retain 50%, 52%, and 57% identities, respectively, with C11. AF3-Rosetta modeling of the BP redesigns predicted similar conformations of the PEB, decreased solvent-accessible surface area of the bilin binding site, an additional predicted hydrogen bond in C11-620, and a more rigid protein backbone. The new constraints on bilin binding improved the stability, absorption properties and fluorescence yields for C11-578, C11-620, and C11-756, and the brightness of the redesigns improved up to 13-fold, approaching the values for the native CpcA-PEB BP. Further design iterations can be used to create a range of absorbing and emitting BPs, including oligomeric assemblies housing internal energy cascades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.